00:17 , May 18, 2019 |  BioCentury  |  Politics, Policy & Law

Cutting through the noise: the handful of pricing proposals the Trump administration or Congress may enact

Scores of proposals for reducing the cost of drugs are swirling around Congress, the White House and the U.S. Department of Health and Human Services, but only a few merit attention outside the beltway. Eliminating...
19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
00:48 , May 17, 2019 |  BC Innovations  |  Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

Model-informed drug development is poised to move into personalized dosing, with a little help from exosomes. An August FDA workshop aims to shed light on when and how to use these precision dosing models in...
00:00 , May 17, 2019 |  BC Innovations  |  Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
22:06 , May 16, 2019 |  BC Extra  |  Preclinical News

Synthetic pH-responsive proteins could deliver biologics via endosomal escape

A study from David Baker's lab described de novo proteins engineered to selectively disrupt endosomal membranes, opening the door to synthetic delivery vehicles that could one day replace viral vectors. The challenge of delivering biologics...
19:53 , May 13, 2019 |  BC Extra  |  Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
01:50 , May 10, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

While the gut microbiome has attracted wide attention for its influence on anti-tumor immunity, a growing body of research suggests microbes living in the tumor itself may play even broader roles in cancer. At least...
19:20 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

The GJA1 inhibitor clofazimine to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies identified clofazimine as a GJA1 inhibitor that could help treat glioblastoma. Screening of a library of 727 FDA-approved small molecules in cell-based activity assays...
00:21 , May 3, 2019 |  BC Innovations  |  Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
22:33 , May 2, 2019 |  BC Innovations  |  Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...